Figure 2From: Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteinsMean and median ratios to baseline for sVEGFR-3 at each timepoint in various treatment cycles. The format follows the same convention as in Figure 1.Back to article page